Collaborating to improve treatment for chronic lymphocytic leukemia and B-cell lymphomas

Who could benefit from this research

What this research studies

This research focuses on enhancing patient care and survival for individuals with chronic lymphocytic leukemia (CLL) and B-cell lymphomas, which are among the most common adult blood cancers. The approach involves developing and managing a portfolio of clinical trials, including those sponsored by the National Cancer Institute (NCI). Patients may have the opportunity to participate in innovative trials aimed at overcoming resistance to therapy and improving treatment outcomes. The research is led by Dr. Deborah Stephens at the Huntsman Cancer Institute, who is dedicated to advancing the standard of care for these conditions.

Why it matters

Where this research is happening

• Univ of North Carolina Chapel Hill
  Chapel Hill, United States Active

Researchers

• Principal investigator: Stephens, Deborah — Univ of North Carolina Chapel Hill
• Study coordinator: Stephens, Deborah

Related research

Other NIH-funded projects on the same topics.

• Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome

  A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11391354

• Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults

  A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11383115

• AVO: a new triplet therapy for untreated high-risk CLL

  A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11382050

• Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia

  A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.

  NIH research Stanford University · Stanford, United States · NIH-11367607

• METTL3's role in driving a stubborn form of chronic lymphocytic leukemia

  A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11364209

• Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia

  Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11355604

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.